Adheron Therapeutics
Latest round
- Series C
Last raised
- Oct 2012
Total raised
- $8.2M
Investors
- 3
About Adheron Therapeutics
Adheron Therapeutics, Inc.Adheron Therapeutics develops therapies for autoimmune and inflammatory diseases, founded in 2006 in Berkeley, US. The firm was acquired by Roche Holding AG in October 2015 for USD 105 mn.Adheron Therapeutics focuses on developing innovative therapies aimed at addressing autoimmune, inflammatory, and fibrotic diseases, with a core emphasis on Cadherin-11 (Cad-11) inhibitors. These products are designed to disrupt pathological fibrosis and inflammatory pathways that lead to chronic conditions such as rheumatoid arthritis and various fibrotic disorders in organs like the lungs and skin. Adheron aims to provide relief and improve the quality of life for patients suffering from debilitating health issues, leveraging the pioneering discoveries of Dr. Michael Brenner.Adheron Therapeutics operates on a business model that encompasses direct partnerships with pharmaceutical companies and academic institutions, facilitating collaborative research and development. Revenue generation is driven primarily through licensing agreements and partnerships that support the commercialization of their Cad-11 inhibitor therapies. Transactions may involve formal agreements for research collaborations, supply agreements for clinical trial materials, and potential profit-sharing arrangements for successful product launches.Adheron Therapeutics plans to utilize its recent acquisition by Roche Holding AG in October 2015 for USD 105 mn to enhance its research and development on new Cad-11 inhibitor therapies. The company is expected to expand its clinical trials and initiatives in North America and Europe, aiming to introduce new products addressing fibrotic and autoimmune diseases by 2025. These efforts will be supported by strategic partnerships and collaborative agreements established during its operational growth.
Who invested in Adheron Therapeutics
3 investors across 3 rounds
See all investors in Adheron Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Adheron Therapeutics
Who invested in Adheron Therapeutics?
Adheron Therapeutics has 3 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Adheron Therapeutics raised?
Adheron Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Adheron Therapeutics last raise money?
Adheron Therapeutics's most recent round on record is a Series C, in Oct 2012.
What does Adheron Therapeutics do?
Adheron Therapeutics is a pharmaceuticals company.
Where is Adheron Therapeutics headquartered?
Adheron Therapeutics is headquartered in Berkeley, US.
Which VCs invest in companies like Adheron Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Adheron Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Adheron Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.